XML 39 R28.htm IDEA: XBRL DOCUMENT
v3.23.3

Revenue Recognition (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2023
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | Segment information is as follows (in thousands):
| Three Months Ended September 30, 2023 |  | Three Months Ended September 30, 2022
| Performance Enzymes |  | Novel Biotherapeutics |  | Total |  | Performance Enzymes |  | Novel Biotherapeutics |  | Total
Major products and service: |  |  |  |  |  |  |  |  |  |  |
Product revenue | $ | 5,395 |  |  | $ | — |  |  | $ | 5,395 |  |  | $ | 28,042 |  |  | $ | — |  |  | $ | 28,042 |
Research and development revenue | 3,315 |  |  | 567 |  |  | 3,882 |  |  | 3,104 |  |  | 3,324 |  |  | 6,428 |
Total revenues | $ | 8,710 |  |  | $ | 567 |  |  | $ | 9,277 |  |  | $ | 31,146 |  |  | $ | 3,324 |  |  | $ | 34,470 |
Primary geographical markets: |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 4,278 |  |  | $ | — |  |  | $ | 4,278 |  |  | $ | 3,654 |  |  | $ | 1,168 |  |  | $ | 4,822 |
EMEA | 2,624 |  |  | 567 |  |  | 3,191 |  |  | 3,831 |  |  | 2,156 |  |  | 5,987 |
APAC | 1,808 |  |  | — |  |  | 1,808 |  |  | 23,661 |  |  | — |  |  | 23,661 |
Total revenues | $ | 8,710 |  |  | $ | 567 |  |  | $ | 9,277 |  |  | $ | 31,146 |  |  | $ | 3,324 |  |  | $ | 34,470 |
| Nine Months Ended September 30, 2023 |  | Nine Months Ended September 30, 2022
| Performance Enzymes |  | Novel Biotherapeutics |  | Total |  | Performance Enzymes |  | Novel Biotherapeutics |  | Total
Major products and service: |  |  |  |  |  |  |  |  |  |  |
Product revenue | $ | 24,807 |  |  | $ | — |  |  | $ | 24,807 |  |  | $ | 93,376 |  |  | $ | — |  |  | $ | 93,376 |
Research and development revenue | 12,696 |  |  | 6,079 |  |  | 18,775 |  |  | 7,398 |  |  | 7,441 |  |  | 14,839 |
Total revenues | $ | 37,503 |  |  | $ | 6,079 |  |  | $ | 43,582 |  |  | $ | 100,774 |  |  | $ | 7,441 |  |  | $ | 108,215 |
Primary geographical markets: |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 8,865 |  |  | $ | 1,933 |  |  | $ | 10,798 |  |  | $ | 8,514 |  |  | $ | 3,653 |  |  | $ | 12,167 |
EMEA | 10,484 |  |  | 4,146 |  |  | 14,630 |  |  | 11,017 |  |  | 3,788 |  |  | 14,805 |
APAC | 18,154 |  |  | — |  |  | 18,154 |  |  | 81,243 |  |  | — |  |  | 81,243 |
Total revenues | $ | 37,503 |  |  | $ | 6,079 |  |  | $ | 43,582 |  |  | $ | 100,774 |  |  | $ | 7,441 |  |  | $ | 108,215 |
Contract with Customer | The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands):
| September 30, 2023 |  | December 31, 2022
Contract assets | $ | 1,936 |  |  | $ | 2,116 |
Unbilled receivables | $ | 5,661 |  |  | $ | 7,016 |
Contract costs | $ | — |  |  | $ | 19 |
Contract liabilities: deferred revenue | $ | 19,336 |  |  | $ | 30,609 |
We recognized the following revenues (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
Revenue recognized in the period for: | 2023 |  | 2022 |  | 2023 |  | 2022
Amounts included in contract liabilities at the beginning of the period: |  |  |  |  |  |  |
Performance obligations satisfied | $ | 1,303 |  |  | $ | 889 |  |  | $ | 9,111 |  |  | $ | 1,694 |
Changes in the period: |  |  |  |  |  |  |
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods | 1,018 |  |  | 495 |  |  | 4,238 |  |  | 365 |
Performance obligations satisfied from new activities in the period - contract revenue | 6,956 |  |  | 33,086 |  |  | 30,233 |  |  | 106,156 |
Total revenues | $ | 9,277 |  |  | $ | 34,470 |  |  | $ | 43,582 |  |  | $ | 108,215 |
Performance Obligation, Expected Timing of Satisfaction | The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2023.The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of September 30, 2023 (in thousands):
| Remainder of 2023 |  | 2024 |  | 2025 |  | 2026 and Thereafter |  |  |  | Total
Product revenue | $ | 8,446 |  |  | $ | 9,590 |  |  | $ | 140 |  |  | $ | 500 |  |  |  |  | $ | 18,676 |
Research and development revenue | 660 |  |  | — |  |  | — |  |  | — |  |  |  |  | 660 |
Total revenues | $ | 9,106 |  |  | $ | 9,590 |  |  | $ | 140 |  |  | $ | 500 |  |  |  |  | $ | 19,336 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of expected timing for satisfying remaining performance obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration